Table of Contents PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Disease overview • Understanding disease • Types of prostate cancer • Diagnosis • Key buying criteria PART 06: Pipeline analysis PART 07: Market landscape • Global prostate cancer therapeutics market • Five forces analysis PART 08: Market segmentation by therapy • Hormonal therapy • Chemotherapy • Immunotherapy • Targeted therapy PART 09: Geographical segmentation • Global prostate cancer drugs market by geographical segmentation 2015-2020 • Prostate cancer drugs market in Americas • Prostate cancer drugs market in EMEA • Prostate cancer drugs market in APAC PART 10: Market drivers • Physicians preference toward adopting hormonal therapies • Development of drugs with novel mechanism of action • Availability of large patient pool PART 11: Impact of drivers PART 12: Market challenges • Presence of alternative treatment approaches • High cost of drugs • Adverse side-effects of drugs PART 13: Impact of drivers and challenges PART 14: Market trends PART 15: Vendor landscape • Competitive scenario PART 16: Key vendor analysis Johnson & Johnson • Astellas Pharma • AstraZeneca • Sanofi • AbbVie • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key customer segments of global prostate cancer drugs market Exhibit 03: Snapshot of prostate cancer Exhibit 04: Types of prostate cancer Exhibit 05: Main diagnostic procedures to determine presence of prostate cancer Exhibit 06: Key buying criteria for prostate cancer drugs Exhibit 07: Factors affecting the adoption rates of prostate cancer drugs 2015 and 2020 Exhibit 08: Pipeline analysis of key vendors in global prostate cancer drugs market Exhibit 09: Percentage share of drug candidates by stage of development Exhibit 10: Phase III pipeline portfolio: Global prostate cancer drugs market Exhibit 11: Phase II pipeline portfolio: Global prostate cancer drugs market Exhibit 12: Phase I pipeline portfolio: Global prostate cancer drugs market Exhibit 13: Global prostate cancer therapeutics market snapshot Exhibit 14: Analysis of global prostate cancer therapeutics market Exhibit 15: Pipeline of global prostate cancer drugs Exhibit 16: Global prostate cancer drugs market 2015-2020 ($ billions) Exhibit 17: Opportunity analysis of global prostate cancer drugs market Exhibit 18: Opportunity analysis in developed and emerging markets Exhibit 19: Five forces analysis Exhibit 20: Segmentation of global prostate cancer drugs market by therapy 2015 Exhibit 21: Life cycle analysis of key segments in global prostate cancer drugs market Exhibit 22: Analysis of prostate cancer drugs market by geography Exhibit 23: Segmentation of prostate cancer drugs market based on geography 2015 and 2020 Exhibit 24: Prostate cancer drugs market revenue by geography 2015-2020 ($ billions) Exhibit 25: Prostate cancer drugs market size and forecast in Americas 2015-2020 ($ billions) Exhibit 26: Key trends across various countries in Americas Exhibit 27: Incidence of prostate cancer in key countries of EMEA 2012 Exhibit 28: Prostate cancer drugs market size and forecast in EMEA 2015-2020 ($ billions) Exhibit 29: Trends in prostate cancer therapeutics market in EMEA Exhibit 30: Prostate cancer drugs market in APAC 2015-2020 ($ billions) Exhibit 31: Key drivers and challenges in APAC Exhibit 32: Performance of hormone therapies in 2015 Exhibit 33: Key drugs with novel mechanism of action Exhibit 34: Potential older population with prostate cancer (65 years and above) Exhibit 35: Impact of drivers Exhibit 36: Alternative therapies Exhibit 37: Costs of key prostate cancer drugs ($ thousands) Exhibit 38: Some of the side-effects of drugs Exhibit 39: Force field analysis of drivers and challenges in global prostate cancer drugs market Exhibit 40: Impact of drivers and challenges Exhibit 41: Trend analysis in global prostate cancer drugs market Exhibit 42: Key highlights of targeted therapies and immunotherapies Exhibit 43: New advancements in diagnosis of prostate cancer Exhibit 44: Key late stage pipeline candidates Exhibit 45: Competitive structure analysis of global prostate cancer drugs market 2015 Exhibit 46: Market share analysis 2015 Exhibit 47: Performance/initiatives of existing and upcoming vendors in global prostate cancer drugs market Exhibit 48: Competitive analysis in global prostate cancer therapeutics market Exhibit 49: Market penetration of various prostate cancer drug manufacturers worldwide 2015 Exhibit 50: Regional analysis of vendors in global prostate cancer drugs market Exhibit 51: Johnson & Johnson: Key highlights Exhibit 52: Johnson & Johnson: Strength assessment Exhibit 53: Johnson & Johnson: Strategy assessment Exhibit 54: Johnson & Johnson: Opportunity assessment Exhibit 55: Johnson & Johnson: YoY revenue comparison of Zytiga (Global) 2013-2015 ($ billions) Exhibit 56: Astellas Pharma: Key highlights Exhibit 57: Astellas Pharma: Strength assessment Exhibit 58: Astellas Pharma: Strategy assessment Exhibit 59: Astellas Pharma: Opportunity assessment Exhibit 60: Astellas Pharma: YoY revenue comparison of Xtandi 2014-2015 ($ billions) Exhibit 61: AstraZeneca: Key highlights Exhibit 62: AstraZeneca: Strength assessment Exhibit 63: AstraZeneca: Strategy assessment Exhibit 64: AstraZeneca: Opportunity assessment Exhibit 65: AstraZeneca: YoY revenue and growth rate of Zoladex 2013-2015 ($ millions) Exhibit 66: AstraZeneca: Geographic segmentation of Zoladex 2015 Exhibit 67: AstraZeneca: YoY revenue and growth rate of Casodex 2013-2015 ($ millions) Exhibit 68: AstraZeneca: Geographic segmentation of Zoladex 2015 Exhibit 69: Sanofi: Key highlights Exhibit 70: Sanofi: Strength assessment Exhibit 71: Sanofi: Strategy assessment Exhibit 72: Sanofi: Opportunity assessment Exhibit 73: Sanofi: YoY revenue and growth rate of Jevtana 2013-2015 ($ millions) Exhibit 74: Sanofi: YoY revenue and growth rate of Taxotere 2013-2015 ($ millions) Exhibit 75: AbbVie: Key highlights Exhibit 76: AbbVie: Strength assessment Exhibit 77: AbbVie: Strategy assessment Exhibit 78: AbbVie: Opportunity assessment Exhibit 79: AbbVie: YoY revenue and growth rate of Lupron 2013-2015 ($ millions)

AbbVie, Astellas Pharma, AstraZeneca, Johnson & Johnson, Sanofi, Active Biotech, ADC Therapeutics, Advantagene, Advaxis Pharmaceuticals, ANI Pharmaceuticals, ArQule, Athenex Pharmaceuticals, Bavarian Nordic, Bayer HealthCare, BHR Pharma, BMS, Boehringer Ingelheim, Camurus, Cleveland BioLabs, CureVac, Dendreon, Dextech Medical, Eisai, Endo Pharmaceuticals, Ferring Pharmaceutical, Foresee Pharmaceuticals, GlaxoSmithKline, GTx, Innocrin Pharmaceutical, Inspyr Therapeutics, Io Therapeutics, Lidds AB, Merck Group, Myovant Sciences, Northwest Biotherapeutics, Novartis, Nymox Pharmaceuticals, OncoGenex, Oncolytics Biotech, Orion, Pharmamar, Progenics Pharmaceuticals, Sotio, Spectrum Pharmaceuticals, Synta, Takeda Pharmaceuticals, Teva Pharmaceutical, Tokai Pharmaceuticals.